Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,752.40
(
-0.18%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
104.43
(
-2.02%
)
Bitcoin
69,898.84
(
-1.88%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 143926

Wednesday, 12/16/2015 11:33:28 AM

Wednesday, December 16, 2015 11:33:28 AM

Post# of 257262
NICE rejects Opdivo reimbursement in second-line NSCLC:

http://www.reuters.com/article/us-bristol-myers-cancer-britain-idUSKBN0TZ1HT20151216

In draft guidance issued on Wednesday, the National Institute for Health and Care Excellence (NICE) said using Opdivo, or nivolumab, in non-small cell lung cancer after chemotherapy did not represent a cost-effective use of resources.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now